MedTrace Logo

Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression

NCT01309581 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2013-08-30

Study results available
· View outcomes & findings →

Summary

The primary objectives of this study are to investigate the potential for ketamine anesthesia to increase the antidepressant efficacy of Electroconvulsive therapy (ECT) and to decrease acute ECT-induced adverse cognitive effects.

Conditions

Interventions

DRUG

Ketamine

Ketamine 1-2 mg/kg IV as indicated for ECT

DRUG

Methohexital

Methohexital 1 mg/kg IV as indicated for ECT

Sponsors & Collaborators

  • James Murrough

    lead OTHER

Principal Investigators

  • James W Murrough, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01309581 on ClinicalTrials.gov